In terms of operational updates, BioAge highlighted positive interim Phase 1 data for its lead product candidate, BGE-102, a small-molecule NLRP3 inhibitor. The data demonstrated significant reductions in inflammatory biomarkers associated with cardiovascular risk, with a Phase 2a proof-of-concept trial planned to initiate in the first half of 2026. Additionally, the company is expanding the indication for BGE-102 into ophthalmology, with a Phase 1b/2a trial in diabetic macular edema expected to start in mid-2026. BioAge also completed a follow-on public offering in February 2026, raising approximately $132.3 million, which will support its expanding clinical programs. CEO Kristen Fortney emphasized the potential of BGE-102 to deliver effective anti-inflammatory treatment in a convenient oral form, positioning it as a versatile candidate across multiple therapeutic areas. Overall, the financial results and operational advancements reflect a positive trajectory for BioAge Labs as it continues to develop innovative therapies targeting aging-related diseases.
2026-03-24 13:11:48
BioAge Labs Reports Full Year 2025 Financial Results with Positive Updates on BGE-102 Development
Expected Stock impact: Noticeably Positive
BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, has announced its financial results for the year ended December 31, 2025, along with significant business updates. The company reported collaboration revenue of $9.0 million for 2025, a notable increase from no revenue in 2024, attributed to its multi-year research collaboration with Novartis that commenced in 2025. Research and development expenses rose to approximately $73.9 million, up from $59.0 million in the previous year, primarily due to increased costs associated with ongoing clinical trials and new programs. The net loss for the year was $80.6 million, or $2.24 per share, compared to a net loss of $71.1 million, or $6.63 per share, in 2024. As of December 31, 2025, BioAge had approximately $285.1 million in cash, cash equivalents, and marketable securities, which the company estimates will be sufficient to fund operations through 2029.
In terms of operational updates, BioAge highlighted positive interim Phase 1 data for its lead product candidate, BGE-102, a small-molecule NLRP3 inhibitor. The data demonstrated significant reductions in inflammatory biomarkers associated with cardiovascular risk, with a Phase 2a proof-of-concept trial planned to initiate in the first half of 2026. Additionally, the company is expanding the indication for BGE-102 into ophthalmology, with a Phase 1b/2a trial in diabetic macular edema expected to start in mid-2026. BioAge also completed a follow-on public offering in February 2026, raising approximately $132.3 million, which will support its expanding clinical programs. CEO Kristen Fortney emphasized the potential of BGE-102 to deliver effective anti-inflammatory treatment in a convenient oral form, positioning it as a versatile candidate across multiple therapeutic areas. Overall, the financial results and operational advancements reflect a positive trajectory for BioAge Labs as it continues to develop innovative therapies targeting aging-related diseases.
In terms of operational updates, BioAge highlighted positive interim Phase 1 data for its lead product candidate, BGE-102, a small-molecule NLRP3 inhibitor. The data demonstrated significant reductions in inflammatory biomarkers associated with cardiovascular risk, with a Phase 2a proof-of-concept trial planned to initiate in the first half of 2026. Additionally, the company is expanding the indication for BGE-102 into ophthalmology, with a Phase 1b/2a trial in diabetic macular edema expected to start in mid-2026. BioAge also completed a follow-on public offering in February 2026, raising approximately $132.3 million, which will support its expanding clinical programs. CEO Kristen Fortney emphasized the potential of BGE-102 to deliver effective anti-inflammatory treatment in a convenient oral form, positioning it as a versatile candidate across multiple therapeutic areas. Overall, the financial results and operational advancements reflect a positive trajectory for BioAge Labs as it continues to develop innovative therapies targeting aging-related diseases.
